<DOC>
	<DOCNO>NCT01134861</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug combine chemotherapy radiation therapy may kill tumor cell . PURPOSE : Randomized phase III trial compare effectiveness various schedule radiation therapy combination chemotherapy use vinblastine cisplatin cisplatin etoposide treat patient stage II stage III non-small cell lung cancer remove surgically .</brief_summary>
	<brief_title>Radiation Therapy Plus Chemotherapy Treating Patients With Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare survival rate patient locally advance , unresectable non-small cell lung cancer randomize concomitant vinblastine/cisplatin ( VBL/CDDP ) thoracic radiotherapy versus sequential VBL/CDDP once-daily thoracic radiotherapy . II . Compare survival rate patient randomize 2 course concomitant etoposide/cisplatin hyperfractionated thoracic radiotherapy versus sequential VBL/CDDP once-daily thoracic radiotherapy . III . Assess frequency treatment-related esophageal hematologic toxicity/morbidity patient concomitant versus sequential chemoradiation treatment arm . OUTLINE : Randomized study . The following acronym use : CDDP Cisplatin , NSC-119875 VBL Vinblastine , NSC-49842 VP-16 Etoposide , NSC-141540 Arm I : 2-Drug Combination Chemotherapy Followed Radiotherapy . CDDP/VBL ; follow thoracic irradiation use photon least 6 MV ( electron may use boost supraclavicular lymph node ) . Arm II : Radiotherapy plus 2-Drug Combination Chemotherapy . Thoracic irradiation use equipment Arm I ; plus CDDP/VBL . Arm III : Hyperfractionated Radiotherapy plus 2-Drug Combination Chemotherapy . Thoracic irradiation use equipment Arm I ; plus CDDP/VP-16 . PROJECTED ACCRUAL : A total 597 patient enter 3.1-4.2 year . If few 6 patients/month accrue , feasibility study re-evaluated .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Locoregionally advance , inoperable , nonsmall cell lung cancer evidence distant metastasis , i.e . : Stage II/IIIA medically inoperable disease Stage IIIA/IIIB unresectable disease No pleural effusion Appearance invasive thoracic procedure allow No 5 % weight loss within 3 month prior diagnosis Confirmed N2 disease first evaluate protocol RTOG9309 PATIENT CHARACTERISTICS : Age : At least 18 Performance status : Karnofsky 70 % 100 % Hematopoietic : AGC least 2,000 Platelets least 100,000 Hemoglobin least 8.0 g/dL Hepatic : ( unless abnormality cause benign disease ) Bilirubin 1.5 time normal AST 1.5 time normal Renal : Creatinine 1.5 mg/dL Cardiovascular : No myocardial infarction within past 6 month No angina No congestive heart failure No uncontrolled arrhythmia Other : No synchronous prior invasive malignancy within 3 year except nonmelanomatous skin cancer No pregnant woman Effective contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior thoracic neck radiotherapy Surgery : No prior complete nearly complete tumor resection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>